ACSS3

Across TCGA pan-cancer cohorts, ACSS3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACSS3 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACSS3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACSS3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where ACSS3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.827	0.313	.003	12	view →
LSCC	OS	Quartile	II,III,IV	0.648	1.000	.013	11	view →
PDAC	OS	Tertile	II,III,IV	1.000	0.782	.002	11	view →
UCEC	DFS	Tertile	II,III,IV	0.505	0.916	.043	4	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	4	view →
GBM	OS	Quartile	All	0.996	0.763	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACSS3–LUAD (DFS)

Open the LUAD breakdown →